MedMira Inc. (FRA:47M)
Germany · Delayed Price · Currency is EUR | Market Cap | 30.41M -0.1% |
| Revenue (ttm) | 232.05K +45.7% |
| Net Income | -1.88M |
| EPS | -0.00 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.0370 |
| Previous Close | 0.0370 |
| Day's Range | 0.0370 - 0.0370 |
| 52-Week Range | 0.0210 - 0.0570 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 27, 2026 |
About MedMira
MedMira Inc., a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV ... [Read more]
Financial Performance
In fiscal year 2025, MedMira's revenue was 240,509, a decrease of -41.70% compared to the previous year's 412,568. Losses were -4.52 million, 36.0% more than in 2024.
Financial numbers in CAD Financial StatementsNews
MedMira Reports Third Quarter Results FY2026
HALIFAX, NS / ACCESS Newswire / June 29, 2026 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2026. Corporate update During Q3 FY2026, the ...
MedMira Reports Second Quarter Results FY2025
HALIFAX, NS / ACCESS Newswire / April 1, 2026 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2026. Corporate update In Q2 FY2026, the Co...
MedMira Reports First Quarter Results FY2026
HALIFAX, NOVA SCOTIA / ACCESS Newswire / December 30, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2025. Corporate update In Q1 F...
MedMira Reports FY2025 Fourth Quarter and Year End Financial Results
HALIFAX, NOVA SCOTIA / ACCESS Newswire / November 28, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2025. Corporate update In ...
Health Canada Approves MedMira's Reveal(R) Rapid TP Test - Urgent New Tool In The Battle Against Syphilis
HALIFAX, NOVA SCOTIA / ACCESS Newswire / August 26, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received approval from Health Canada for its Reveal® TP (Syphilis) Antibody Tes...
MedMira Announces Launch of Clinical Trial for Its Multiplo(R) TP/HIV Self-Test in Canada
HALIFAX, NS / ACCESS Newswire / July 7, 2025 / MedMira Inc. (MedMira) (TSXV: MIR) and REACH Nexus are excited to announce a clinical trial has officially started earlier than anticipated to evaluate M...
MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal(R) G4 HIV-1/2 rapid test for VA, Department of Defense
HALIFAX, NS / ACCESS Newswire / April 17, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) and Lovell® Government Services announced today that they have partnered to serve federal healthcare systems such as ...
MedMira Announces Partnership with MediGroup Physician Services in the United States
HALIFAX, NS / ACCESS Newswire / February 27, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today its partnership with MediGroup, a leader in the US health care industry since 1999. This new partn...
MedMira Announces Exclusive Distribution Agreement with Trimedic Inc. for Canada
HALIFAX, NS / ACCESS Newswire / February 25, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today its exclusive distribution agreement with Trimedic Inc. for the Canadian market. This partnership ...
MedMira Receives Investigational Testing Authorizations for Multiplo(R) TP/HIV Self-Test and Non-Professional Use Applications
MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received Investigational Testing Authorizations (ITAs) from Health Canada to begin clinical trials for new label claim applications of its...
MedMira Receives Health Canada Approval for Its Reveal(R) G4 Rapid HIV-1/2 Test for Point-of-Care Use
MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today the approval from Health Canada for its Reveal®Rapid G4 HIV-1/2 Test (Reveal® HIV test) for Point-of-Care (POC) use. The Re...
MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
HALIFAX, NS / ACCESSWIRE / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical trial...
MedMira Reports First Quarter Results FY2025
HALIFAX, NS / ACCESSWIRE / December 30, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2024. Corporate update During Q1 FY2025, Med...
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV
HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo® Rap...
MedMira Reports FY2024 Fourth Quarter and Year End Financial Results
HALIFAX, NS / ACCESSWIRE / November 28, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2024. Corporate Update In December 2023,...
MedMira Announces the appointment of Vice President of Commercial Operations
MedMira Inc. continues its North-American expansion plan HALIFAX, NS / ACCESSWIRE / October 3, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) today announced the appointment of Nicole Crenshaw as Vic...
MedMira Reports Third Quarter Results FY2024
HALIFAX, NS / ACCESSWIRE / July 2, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2024. Corporate update In Q3 FY2024, MedMira focuse...
MedMira Announces the Hire of Vice President of Business Development
HALIFAX, NS / ACCESSWIRE / April 30, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to announce the expansion of their commercialisation team by welcoming Ms. Rene Bell to the position of ...
MedMira Reports Second Quarter Results FY2024
HALIFAX, NS / ACCESSWIRE / April 1, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2024. Corporate update During Q2 FY2024, MedMira...
MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System
HALIFAX, NS / ACCESSWIRE / March 13, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of a Canadian patent patent (number 2,949,634) for its new innovative and quantitative test s...
CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira's Products
Correction: Extended clarification. HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update on the ongoing review process by Health Canad...
Corporate Update on Clinical Evaluation of MedMira's Products
HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update on the ongoing review process by Health Canada. The Company made the required sub...
MedMira Reports First Quarter Results FY2024
HALIFAX, NS / ACCESSWIRE / December 29, 2023 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2023. Corporate update During Q1 FY2024, Med...
U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test
HALIFAX, NOVA SCOTIA / ACCESSWIRE / December 13, 2023 / MedMira Inc. (MedMira) (TSXV:MIR) proudly announces today the successful attainment of 510(k) clearance for the HIV-2 claim on the Reveal® G4 Ra...
MedMira Reports FY2023 Fourth Quarter and Year End Financial Results
HALIFAX, NS / ACCESSWIRE / November 28, 2023 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2023. Corporate Update Throughout the re...